{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"GRI Bio, Inc."},"Symbol":{"label":"Symbol","value":"GRI"},"Address":{"label":"Address","value":"100 N 18TH STREET,TWO LOGAN SQUARE, SUITE 300,LA JOLLA, CA, PHILADELPHIA, Pennsylvania, 19103, United States"},"Phone":{"label":"Phone","value":"+1 267 207-3606"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"GRI Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a pipeline of Natural Killer T (NKT) modulating therapies for the treatment of inflammatory, fibrotic and autoimmune diseases. The Company's lead program, GRI-0621 is a small molecule RAR-beta dual agonist that inhibits the activity of human Type I, or invariant, NKT (iNKT) cells, which is being developed for the treatment of Idiopathic pulmonary fibrosis (IPF). GRI-0621 is a once-daily oral capsule for several fibrotic indications. The Company's second asset GRI-0803, is a novel activator of human Type 2 NKT cells in development for the treatment of autoimmune disorders, with an initial focus on systemic lupus erythematosus. Additionally, the Company has a library of 500+ proprietary compounds targeting a number of high value indications with unmet need."},"CompanyUrl":{"label":"Company Url","value":"https://www.gribio.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Albert Agro","title":"Chief Medical Officer"},{"name":"Vipin Kumar Chaturvedi","title":"Chief Scientific Officer"},{"name":"W. Marc Hertz","title":"President, Chief Executive Officer & Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}